Education
About Us
Working with TipRanks
Follow Us
Relay Therapeutics (RLAY)
NASDAQ:RLAY
RLAY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.85 - $10.72
Previous CloseN/A
Volume391.09K
Average Volume (3M)2.26M
Market Cap
$484.83M
Enterprise Value-$43.39M
Total Cash (Recent Filing)$124.29M
Total Debt (Recent Filing)$48.50M
Price to Earnings (P/E)―
Beta2.42
Next Earnings
May 01, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding169,521,850
10 Day Avg. Volume2,817,617
30 Day Avg. Volume2,261,670
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)51.84
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.34
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
$17.00Price Target Upside468.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Relay Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyThe combination of RLY-2608 and Faslodex achieved a 38.7% objective response rate in patients with PIK3CA-mutant, HR+/HER2- metastatic breast cancer, indicating promising efficacy.
Partnerships And CollaborationsScorpion has a collaboration with Pfizer to evaluate the triplet combination of STX-478 + atirmociclib + fulvestrant in frontline patients with PI3Kα-mutated HR +/HER2- metastatic breast cancer.
Bears Say
Pipeline DelaysThe initiation of clinical trials for the NRAS and Fabry programs will be delayed to optimize resource allocation.
Price Target AdjustmentThe launch dates for RLY-2608 have been delayed, which lowers the price target to $12 from $21.
---
Ownership Overview
2.91% Insiders
16.98% Mutual Funds
48.39% Other Institutional Investors
16.43% Public Companies and
Individual Investors
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $2.85 and its highest was $10.72 in the past 12 months.
What is Relay Therapeutics’s market cap?
Relay Therapeutics’s market cap is $484.83M.
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 34 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Feb 26, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.561 by $0.111.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -0.52.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 169,521,850 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.561. Following the earnings report the stock price went down -13.333%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Currently, no hedge funds are holding shares in RLAY
---
Relay Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (468.56% Upside)
$17.00 (468.56% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 27.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.21%
12-Months-Change
Fundamentals
Return on Equity
-44.15%
Trailing 12-Months
Asset Growth
3.24%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
---
RLAY Stock 12 Month Forecast
Average Price Target
$17.00
▲(468.56% Upside)
Technical Analysis
Best Analysts Covering RLAY
1 Year
1 Year Success Rate
0/27 ratings generated profit
1 Year Average Return
-41.04%
reiterated a buy rating 29 days ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -41.04% per trade.
---